Treatment of bullous impetigo and the staphylococcal scalded skin syndrome in infants

References

• Resnick SD. Staphylococcal and streptococcal skin infections: pyodermas and toxin-mediated syndromes. In: Textbook of Pediatric Dermatology. Harper J, Oranje A, Prose N (Eds). Blackwell Science Ltd, Oxford, UK (2000).
   Google Scholar
• •• Excellent clinical overview of staphylococcal and streptococcal skin infections.
   Google Scholar
• Lee P, Zipoli M, Weinberg A, Swartz M, Johnson R. Pyodermas: Staphylococus aureus, Streptococcus and other Gram-positive bacteria. In: Fitzpatrick's Dermatology in General Medicine. Freedberg I, Eisen A, Wolff K, Austen K, Goldsmith L, Katz S (Eds). McGraw-Hill, NY, USA (2003).
   Google Scholar
• •• Superbly detailed clinical account.
   Google Scholar
• Eriksen NH, Espersen F, Rosdahl VT, Jensen K. Carriage of Staphylococcus aureus among 104 healthy persons during a 19 month period. Epidemiol. Infect. 115(1), 51–60 (1995).
   Google Scholar
• Fritsch P, Elias P. Varga J. The fate of staphylococcal exfoliatin in newborn and adult mice. Br. J. Dermatol. 95(3), 275–284 (1976).
   PubMed Web of Science ®Google Scholar
• Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nature Med. 6(11), 1275–1277 (2000).
   PubMed Web of Science ®Google Scholar
• • Important paper on the action of exfoliative toxins (ETs).
   Google Scholar
• Resnick S, Fritsch P, Elias P. The staphylococcal scalded skin and toxic shock syndromes. In: Physiology, biochemistry and molecular biology of the skin. Goldsmith L (Ed.). Oxford University Press, Oxford, UK (1991).
   Google Scholar
• Monday SR, Vath GM, Ferens WA et al. Unique superantigen activity of staphylococcal exfoliative toxins. J. Immund 162(8), 4550–4559 (1999).
   PubMed Web of Science ®Google Scholar
• •• Represents one side of the currentcontroversy on the properties of ETs.
   Google Scholar
• Feingold DS. Staphylococcal and streptococcal pyodermas. Semin. DermatoL 12(4), 331–335 (1993).
   PubMedGoogle Scholar
• Florman A, Holzman R Nosocomial scalded skin syndrome. Ritter's disease caused by phage group 3 Staphylococcus aureus. Am. J. Dis. Child 134,1043–1045 (1980).
   PubMedGoogle Scholar
• Hlady WG, Middaugh JP. An epidemic of bullous impetigo in a newborn nursery due to Staphylococcus aureus: epidemiology and control measures. Alaska Med 28(4), 99–103 (1986).
   Google Scholar
• Hoeger PH, Elsner R Staphylococcal scalded skin syndrome: transmission of exfoliatin-producing Staphylococcus aureus by an asymptomatic carrier. Pediatr. Infect. Dis. J. 7(5), 340–342 (1988).
   Google Scholar
• Dancer SJ, Simmons NA, Poston SM, Noble WC. Outbreak of staphylococcal scalded skin syndrome among neonates. J. Infect. 16(1), 87–103 (1988).
   PubMed Web of Science ®Google Scholar
• Patel GK, Varma S, Finlay AY. Staphyloccocal scalded skin syndrome in healthy adults. Br. J. DermatoL 142(6), 1253–1255 (2000).
   PubMed Web of Science ®Google Scholar
• Johnston GA, Ghura HS, Carter E, Graham-Brown RA. Neonatal erythema multiforme major. Clin. Exp. DermatoL 27(8), 661–664 (2002).
   PubMed Web of Science ®Google Scholar
• Elias P, Fritsch P, Epstein E. Staphylococcal scalded skin syndrome. Arch. Dermatol. 113, 207–219 (1977).
   PubMedGoogle Scholar
• Elias PM, Fritsch R Epstein EH. Staphylococcal scalded skin syndrome. Clinical features, pathogenesis and recent microbiological and biochemical developments. Arch. DermatoL 113(2), 207–219 (1977).
   PubMedGoogle Scholar
• Patel GK, Finlay AY. Staphylococcal scalded skin syndrome: diagnosis and management. Am. J. Clin. DermatoL 4(3), 165–175 (2003).
   PubMed Web of Science ®Google Scholar
• Couppie P, Sainte-Marie D, Prevost G et al. Impetigo in French Guyana. A clinical, bacteriological, toxicological and sensitivity to antibiotics study. Ann. DermatoL Venered 125(10), 688–693 (1998).
   PubMed Web of Science ®Google Scholar
• Rortveit S, Rortveit G. An epidemic of bullous impetigo in the municipality of Austevoll in the year 2002. Tidsskr Nor Laegefbren 123(18), 2557–2560 (2003).
   Google Scholar
• McLinn S. Topical mupirodn versus systemic erythromycin treatment for pyoderma. Pediatr Infict. Dis. J. 7(11), 785–790 (1988).
   PubMed Web of Science ®Google Scholar
• Bradley SF, Ramsey MA, Morton TM, Kauffman CA. Mupirocin resistance: clinical and molecular epidemiology. Infict. Cont. Hosp. EpidemioL 16(6), 354–358 (1995).
   PubMed Web of Science ®Google Scholar
• Katz BE, Fisher AA. Bacitracin: a unique topical antibiotic sensitizer. J. Am. Acad Dermatol. 17(6), 1016–1024 (1987).
   PubMed Web of Science ®Google Scholar
• Gollhausen R, Enders F, Przybilla B, Burg G, Ring J. Trends in allergic contact sensitization. Contact Dermatitis 18(3), 147–154 (1988).
   PubMed Web of Science ®Google Scholar
• Hedrick J. Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr Drugs 5\(Suppl. 1), 35–46 (2003).
   PubMedGoogle Scholar
• Amaya-Tapia G, Aguirre-Avalos G, Andrade-Villanueva J et al. Once-daily azithromycin in the treatment of adult skin and skin-structure infections. j Antimicrob. Chemother. 31(Suppl. E), 129–135 (1993).
   Google Scholar
• Feder HM Jr, Pond KE. Addition of rifampin to cephalexin therapy for recalcitrant staphylococcal skin infections — an observation. Clin. Pediatr (Phila.) 35(4), 205–208 (1996).
   PubMed Web of Science ®Google Scholar
• Zafar AB, Butler RC, Reese DJ, Gaydos LA, Mennonna PA. Use of 0.3% triclosan (Bacti-Stat) to eradicate an outbreak of methicillin-resistant Staphylococcus aureus in a neonatal nursery. Am. J. Infect. Cont. 23(3), 200–208 (1995).
   Google Scholar
• Kauffman CA, Terpenning MS, He X et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term care facility with the use of mupirocin ointment. Am. J. Med 94(4), 371–378 (1993).
   Google Scholar
• Spicer WJ. Three strategies in the control of staphylococci including methicillin-resistant Staphylococcus aureus. J. Hy. Infect. 5(Suppl. A), 45–49 (1984).
   Google Scholar
• Report of a combined working party of the British Society for Antimicrobial Chemotherapy, the Hospital Infection Society and the Infection Control Nurses Association. Revised guidelines for the control of methicillin-resistant Staphylococus aureus infection in hospitals. J. Hy. Infect. 39, 253–290 (1998).
   PubMed Web of Science ®Google Scholar
• Kotra L, Samama J, Mobashery S. P-lactamases and resistance to P-lactam antibiotics. In: Bacterial Resistance to Antimicrobials. Lewis KS, Taber HW, Wax RG (Eds). Marcel Decker, NY, USA (2002).
   Google Scholar
• • Useful update on bacterial resistance.
   Google Scholar
• Samaha-Kfoury J, Arai G. Recent developments in P-lactamases and extended spectrum P-lactamases. Br Med J. 327, 1209–1213 (2003).
   PubMed Web of Science ®Google Scholar
• Duckworth G. Controlling methicillin resistant Staphylococcus aureus. Br. Med. J. 327(7425), 1177–1178 (2003).
   Google Scholar
• • Concise editorial on the control of methicillin-resistant Staphylococcus aureus.
   Google Scholar
• W Epidemiology of MRSA . Infection 27(Suppl. 2), S13-516 (1999).
   Google Scholar
• Yamaguchi T, Yokota Y, Terajima J et al. Clonal association of Staphylococcus aureus causing bullous impetigo and the emergence of new methicillin-resistant clonal groups in Kansai district in Japan. J. Infect. Dis. 185(10), 1511–1516 (2002).
   Google Scholar
• Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 61(4), 525–551 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34(11), 1481–1490 (2002).
   Google Scholar
• Schweiger ES, Scheinfeld NS, Tischler HR, Weinberg JM. Linezolid and quinupristin/dalfopristin: novel antibiotics for Gram-positive infections of the skin. J. Drugs Dermatol. 2(4), 378–383 (2003).
   PubMedGoogle Scholar
• Schweiger ES, Weinberg JM. Novel antibacterial agents for skin and skin structure infections. J. Am. Acad.Dermatol. 50(3), 331–340 (2004).
   PubMed Web of Science ®Google Scholar
• •• Excellent recent review of latest therapiesfor cutaneous infections.
   Google Scholar
• Baggett HC, Hennessy TW, Leman R An outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect. Cont. Hosp. Epidemiol. 24(6), 397–402 (2003).
   Google Scholar
• Al-Sulami AA, Al-Rubiay KK, Affat AM. An inhibitor of Staphylococcus aureus exfoliative toxin. East Mediterr. Health J. 7(1–2), 121–127 (2001).
   Google Scholar
• Coyle EA. Targeting bacterial virulence: the role of protein synthesis inhibitors in severe infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 23(5), 638–642 (2003).
   PubMed Web of Science ®Google Scholar
• Ciftci E, Guriz H, Aysev AD. Mupirocin versus terbinafine in impetigo. Indian. J. Pediatr. 69(8), 679–682 (2002).
   PubMedGoogle Scholar